Twin Peaks Wealth Advisors’s Regenxbio RGNX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$42	–	1744
2026 Q1	$42	Buy	+5	New	+$53	﹤0.01%	2311

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Twin Peaks Wealth Advisors's RGNX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 5 shares — an estimated $42 sold.

Twin Peaks Wealth Advisors first reported a position in RGNX in Q1 2026 and held it in 1 quarter. The position peaked at $42 in Q1 2026. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 5 Regenxbio shares in Q2 2026, an estimated $42.
Twin Peaks Wealth Advisors first reported a position in Regenxbio in Q1 2026 and held it in 1 quarter.
Twin Peaks Wealth Advisors's Regenxbio position peaked at $42 in Q1 2026.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.